$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Instructions for taking ixazomib
2026-02-01 22:25:32
Check Details
Key precautions before taking ixazomib
2026-02-01 22:25:32
Check Details
Ensidipine application methods and dosage guidance
2026-02-01 22:25:32
Check Details
Analysis of the therapeutic effect of ensidipine on acute myeloid leukemia
2026-02-01 22:25:32
Check Details
Effect of taking ensidipine on survival time
2026-02-01 22:25:32
Check Details
Is ensidipine expected to be included in medical insurance in 2024?
2026-02-01 22:25:32
Check Details
Ensidipine targeted drug survival rate
2026-02-01 22:25:32
Check Details
Analysis of the main application fields and therapeutic efficacy of ensidipine
2026-02-01 22:25:32
Check Details
Which generation of targeted drugs does larotrectinib belong to?
2026-02-01 22:25:32
Check Details
Can larotrectinib treat lung cancer?
2026-02-01 22:25:32
Check Details
Can Larotrectinib Completely Cure?
2026-02-01 22:25:32
Check Details
Has larotrectinib been launched in China and included in medical insurance?
2026-02-01 22:25:32
Check Details
1
2
...
1177
1178
1179
1180
1181
1182
1183
...
10225
10226
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Capivasertib (Truqap) Complete Medication Guide: Indications, Dosing, Safety, and Precautions
2
Cemiplimab Storage and Handling Guide
3
ASCO 2026: Spevatamig Opens a New Path in Pancreatic Cancer Immunotherapy
4
FDA Approves First mRNA Flu Vaccine mFLUSIVA
5
Nintedanib Indications Explained: Beyond Idiopathic Pulmonary Fibrosis
6
How Long Does Belumosudil Take to Work for Pulmonary cGVHD?
7
Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Dosing Duration, Efficacy Comparison, and Long-Term Management
8
Belzutifan (Welireg): Comprehensive Guide to the First HIF-2α Inhibitor — Indications, Dosing, and Safety Monitoring
9
Encorafenib (Braftovi): Comprehensive Guide to BRAF V600 Inhibitor Indications, Dose Regimens by Tumor Type, and Administration Requirements
10
Tazemetostat: Mechanism, Standard Dosing, and the 2026 Global Withdrawal of the First-in-Class EZH2 Inhibitor
11
FDA Approves Orzeyful, the World's First Orexin Receptor Agonist for Narcolepsy Type 1, Ushering in a New Era of Root-Cause Therapy
12
Alpelisib vs Inavolisib: How to Choose Between Two PI3Kα Inhibitors in PIK3CA-Mutated Breast Cancer